# A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

> **NCT04435600** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 139 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT04435600
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-14
- **Primary completion:** 2024-02-12
- **Final completion:** 2024-10-15
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04435600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04435600, "A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04435600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*